共 50 条
- [43] ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer (vol 2, 106, 2022) COMMUNICATIONS MEDICINE, 2023, 3 (01):
- [50] The ENTPD1 promoter polymorphism-860 A > G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk FASEB JOURNAL, 2017, 31 (07): : 2771 - 2784